Kudos to GSK!

My recent curiosity on HPV and cervical-cancer vaccine has caused me to do some research and readings (ahem…ahem… I said ‘just some’). I found out that GlaxoSmithKline has reduced the price of their cervical-cancer vaccine. This is definitely good news to all women. The article I read says:

In an effort to meet the Filipinas need for more affordable health care, GSK has slashed their cervical cancer vaccine, Ceravix, by 71%. The move highlights GSK’s dedication to cervical-cancer prevention and its continued advocacy to give Filipinos quality medicines and vaccines they need at prices they can afford, GSK said. This initiative is GSK’s response to the Filipinos’ need for more affordable health care.

According to GSK president and managing director Rich Gain, The Philippines is the first country where GSK Cervarix is made affordable to all. They (GSK) hope that this will help save more lives and protect women against cervical cancer.

Cervarix, as approved by the Bureau of Food and Drugs, is a vaccine to protect against the two most common cancer-causing types of human pappilomavirus (HPV)-16 and 18. It has also shown efficacy against persistent infection caused by 12 other cancer-causing HPV types. So far, clinical data demonstrated that Cervatix provides this protection.

*Source: Medical Observer, year 17, issue 10, Nov-Dec. 2008